Relmada Therapeutics RLMD
NASDAQ RLMD
$3.21 -0.15 (-4.46%)
At close: Oct 21, 2026 · 4:00 PM EDT

Relmada Therapeutics (RLMD) Gross Margin (2012 - 2013)

Updated

Relmada Therapeutics' Gross Margin came in at 21.31% for FY2013, down 5.66 percentage points from 26.97% in FY2012.

Analysis

Relmada Therapeutics (RLMD) Gross Margin (2012 - 2013) Analysis & Trends

  • Per Business Quant, earlier years put Gross Margin at 26.97% in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 85.78%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 68.19%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 74.74%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 73.54%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 78.02%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 83.60%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 72.04%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 79.76%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 72.78%
10 Relmada Therapeutics 361.29 Mn -197.30 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Nov 30, 2013 8.86%
May 31, 2013 49.21%
Feb 28, 2013 20.55%
Nov 30, 2012 13.91%
Aug 31, 2012 34.13%
May 31, 2012 27.00%
API Access

Relmada Therapeutics Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY